Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SCYNEXIS ( (SCYX) ) has shared an update.
On October 14, 2025, SCYNEXIS and GSK signed a binding memorandum of understanding to amend their exclusive license agreement, resolving a prior disagreement over the Phase 3 MARIO study of ibrexafungerp. SCYNEXIS agreed to terminate the MARIO Study and will receive a $22 million payment from GSK, along with an additional $2.3 million for wind-down activities. GSK remains committed to the commercialization of BREXAFEMME® for VVC and rVVC, with plans to engage with the FDA in 2026 for its U.S. market relaunch. The agreement maintains the potential milestones and royalties for SCYNEXIS, excluding those related to the MARIO Study.
The most recent analyst rating on (SCYX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.
Spark’s Take on SCYX Stock
According to Spark, TipRanks’ AI Analyst, SCYX is a Neutral.
SCYNEXIS’s overall stock score is primarily impacted by its financial performance challenges, including declining revenue, negative profitability, and cash flow issues. Technical analysis suggests potential bearish momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low stock score.
To see Spark’s full report on SCYX stock, click here.
More about SCYNEXIS
SCYNEXIS, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of anti-infective therapies. Its primary product, ibrexafungerp, marketed under the brand name BREXAFEMME®, targets fungal infections such as vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC). The company collaborates with GlaxoSmithKline (GSK) for the global distribution of its products, excluding Greater China and certain other regions.
Average Trading Volume: 331,320
Technical Sentiment Signal: Strong Sell
Current Market Cap: $34.05M
Find detailed analytics on SCYX stock on TipRanks’ Stock Analysis page.